Novartis Inks Second Off-Label Settlement With DoJ, Paying $72.5 Million Over TOBI Marketing

Novartis still faces government investigations over its marketing of five other drugs; FDA issues a warning letter over its promotion of Gleevec on two company-sponsored websites.